oxalis macrantha/fatigue

The tissue adhesive 2-octyl cyanoacrylate (OCA) was encapsulated in polyurethane microshells and incorporated into bone cement to form a catalyst free, self-healing bone cement comprised of all clinically approved components. The bending strength, modulus, and fatigue lifetime were investigated in

Primary biliary cholangitis (PBC) occurs as a result of immune-mediated damage to bile ducts, with an associated inflammatory response leading to progressive fibrosis and loss of patency. This loss of patency leads, in turn, to hepatic accumulation of bile acids, resulting in liver damage with

Patients with primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) and insufficient treatment response or risk factors exhibit a remarkably increased risk for disease progression and associated complications. Furthermore, extrahepatic manifestations may considerably reduce quality

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by chronic cholestasis. Treatment with the accepted primary therapy ursodeoxycholic acid (UDCA) has been shown to be associated with delayed disease progression probably through reduced impact of cholestatic injury on

PBC is a chronic progressive autoimmune disorder involving the destruction of intrahepatic small bile ducts, cholestasis, fibrosis, and ultimately cirrhosis if left untreated. It is largely driven by the autoimmune response, but bile acids and the intestinal microbiota are implicated in disease

BACKGROUND Breast cancer is a major cause of morbidity, mortality, and medical expenditures among women in Canada. Essiac (Resperin Canada Limited, Waterloo, Ontario, Canada), a blend of at least four herbs (burdock root [Arctium lappa], Indian rhubarb [Rheum palmatum], sheep sorrel [Rumex

Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis or cirrhosis. Treatment options are currently limited. Ursodeoxycholic acid (UDCA) remains first-line therapy and has been proven to normalize serum biochemistries, halt histologic disease

The 5-year findings of a randomized clinical trial testing the null hypothesis that there are no differences between the clinical-wear performances of nano-, microfilled-, and conventional hybrids placed in class I and class II cavities are reported. Effects of subject-, operator-, and

OBJECTIVE To investigate the effects of cyclic loading on occlusal contact area (OCA) wear and the possible presence of fatigue wear mechanisms in four composite resins (Silux, Z100, Ariston and Surefil) using a reciprocal compression-sliding test apparatus. METHODS Six specimens were made for each

OBJECTIVE Compare the 3-year clinical performance (wear as an additional parameter) of a nanocomposite and a microhybrid composite, versus ADA guidelines (2001) using direct (clinical/USPHS) and indirect (quantitative/3D laser scan and qualitative/SEM) methods, in parallel. METHODS 18 Filtek Supreme